PF-06648671 is a novel, brain-penetrable, and orally active γ-secretase modulator (GSM) . PF-06648671 reduces Aβ42 and Aβ40, with concomitant increases in Aβ37 and Aβ38 in vitro. PF-06648671 is used for the study of Alzheimer’s disease In Vitro In a cell-based assay, PF-06648671 reduces Aβ42 and Aβ40 , with concomitant increases in Aβ37 and Aβ38, without inhibiting the cleavage of Notch or other substrates. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo PF-06648671 demonstrates reduces Aβ42 within the brain and CSF following acute oral administration in animals . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: γ-secretase